腺囊性癌症的分子进展:遗传和表观遗传的见解
Luciana Oliveira Almeida1, Kevin Luiz Lopes-Delphino2, Isabel Schausltz Pereira Faustino3
1Department of Basic and Oral Biology, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Clinical Analyses, Toxicology, and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
腺囊性癌的遗传和表观遗传变化,包括MYB-NFIB融合和途径失调,驱动瘤的攻击性行为. 了解这些分子驱动因素是开发向治疗和改善患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 腺状囊性癌 (ACC) 由于其复杂的分子形状,在预后,治疗和复发方面存在重大挑战.
- 多学科管理对于解决ACC多方面的性质至关重要.
研究的目的:
- 审查腺囊性癌症的遗传和表观遗传变化.
- 讨论这些改变对预后,治疗和复发的影响.
- 突出ACC多学科管理中的挑战.
主要方法:
- 进行了全面的叙事审查.
- 在包括PubMed,Scopus,Web of Science,EMBASE,LILACS和Google Scholar在内的主要科学数据库中进行了搜索.
- 包括手动验证来自相关期刊文章的参考列表.
主要成果:
- MYB-NFIB融合是ACC的一个决定性基因变异,影响瘤行为和亡耐药性.
- PI3K/AKT和NOTCH通路的异常有助于具有侵略性的特征,如围神经侵入和转移.
- 表观遗传修饰 (DNA甲基化,基因组变化) 和特定蛋白酶 (MMP-9,甲素) 与瘤进展和预后较差有关.
- 尽管ACC的罕见性使临床试验复杂化,但已识别的分子标记提供了潜在的治疗点.
结论:
- ACC复杂的遗传和表观遗传环境需要开发有针对性的治疗方法.
- 未来的研究应该集中在评估分子向治疗和表观遗传干预措施以改善ACC结果的临床试验上.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
